BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38646424)

  • 1. Drug-drug interaction between tacrolimus and caspofungin in Chinese kidney transplant patients with different
    Zhang Y; Shen B; Li Y; Zong H; Zhang X; Cao X; Liu F; Li Y
    Ther Adv Drug Saf; 2024; 15():20420986241243165. PubMed ID: 38646424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients.
    Zhang Y; Du Y; Ren S; Li Y; Zhang X; Cao X; Liu F; Zong H; Li Y
    Ann Pharmacother; 2024 Jun; 58(6):605-613. PubMed ID: 37702380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
    Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
    J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of drug combination on tacrolimus target dose in renal transplant patients with different
    Zhang SF; Tang BH; Wei AH; Du Y; Guan ZW; Li Y
    Xenobiotica; 2022 Mar; 52(3):312-321. PubMed ID: 35395919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artificial Neural Network Analysis of Determinants of Tacrolimus Pharmacokinetics in Liver Transplant Recipients.
    Du Y; Zhang Y; Yang Z; Li Y; Wang X; Li Z; Ren L; Li Y
    Ann Pharmacother; 2024 May; 58(5):469-479. PubMed ID: 37559252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
    Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
    J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
    Chen Z; Cheng X; Zhang L; Tang L; Fang Y; Chen H; Zhang L; Shen A
    Pharmacol Rep; 2021 Oct; 73(5):1418-1426. PubMed ID: 34089513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Tacrolimus Intra-Patient Variability during 6-12 Months after Kidney Transplantation between CYP3A5 Expressers and Nonexpressers.
    Nuchjumroon A; Vadcharavivad S; Singhan W; Poosoonthornsri M; Chancharoenthana W; Udomkarnjananun S; Townamchai N; Avihingsanon Y; Praditpornsilpa K; Eiam-Ong S
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clinical Impact of the C
    van Gelder T; Meziyerh S; Swen JJ; de Vries APJ; Moes DJAR
    Front Pharmacol; 2020; 11():1142. PubMed ID: 32848756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Wuzhi preparations on tacrolimus in CYP3A5 expressers during the early period after transplantation: A real-life experience from heart transplant recipients.
    Zhou Y; Huang X; Liu L; Zeng F; Han Y; Zhang J; Zhou H; Zhang Y
    Transpl Immunol; 2023 Feb; 76():101748. PubMed ID: 36423734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients.
    Yang Y; Huang X; Shi Y; Yang R; Shi H; Yang X; Hao G; Zheng Y; Wang J; Su L; Li Y; Zhao W
    Front Pharmacol; 2021; 12():692922. PubMed ID: 34290611
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation.
    Hirai T; Morikawa Y; Onishi R; Nakatani Y; Nishikawa K; Inoue T; Iwamoto T
    Br J Clin Pharmacol; 2023 Jun; 89(6):1852-1861. PubMed ID: 36640105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of tacrolimus and Wuzhi tablet pharmacokinetic interaction magnitude in renal transplant recipients.
    Chen P; Dai R; She Y; Fu Q; Huang M; Chen X; Wang C
    Clin Transplant; 2022 Dec; 36(12):e14807. PubMed ID: 36057787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.
    Li DY; Teng RC; Zhu HJ; Fang Y
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):466-74. PubMed ID: 23557867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.
    Ebid AIM; Ismail DA; Lotfy NM; Mahmoud MA; ELSharkawy M
    J Clin Pharm Ther; 2022 Dec; 47(12):2255-2263. PubMed ID: 36379901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.